Trump's Order to Boost Domestic Drug Manufacturing Amid Trade War Woes

Strategic Insights -

President Donald Trump has signed an executive order aiming to ease regulations and accelerate approvals for domestic pharmaceutical manufacturing in the United States. The move comes as the White House plans to assess tariffs on imported drugs, a decision that could have far-reaching consequences for patients. Industry experts warn that tariffs could lead to higher prices and potential shortages, while some see the push for domestic manufacturing as a step in the right direction to revitalize an industry that has long been plagued by shortages and regulatory complexities.

Key Takeaways:

  • The executive order signed by Trump on May 5 directs the FDA to speed up approvals and eliminate unnecessary regulations that slow down companies seeking to build pharmaceutical factories in the United States.
  • The order aims to boost domestic manufacturing after decades of the industry moving overseas, where companies can take advantage of cheaper labor and fewer regulatory hurdles.
  • Gilead Sciences has announced plans to spend an additional $11 billion on projects in the United States through this decade, including three new facilities, upgrades to three existing sites, and new technology.
  • Trump has touted projects announced by 10 drug companies, including Abbott Laboratories' $500 million at sites in Texas and Illinois, and Eli Lilly's plans to spend $27 billion to build four new U.S. factories.
  • The FDA will review policies to improve its foreign inspection program, including developing policies that specify FDA inspectors must refuse lodging and transportation from drug and device companies to "maintain the integrity of the oversight process."
  • Analysts question the FDA's authority to force inspections if overseas drug manufacturers refuse access, highlighting the need for more transparency and accountability in the global pharmaceutical industry.
  • Industry experts and advocacy groups have expressed concerns about the potential consequences of tariffs on imported drugs, including higher prices and potential shortages.

Statistics:

  • The global pharmaceutical industry has a 30-year trend of moving manufacturing out of the United States (Source 1: CivicaRx's chief government affairs and public policy officer).
  • The FDA completes about 12,000 domestic inspections and 3,000 foreign inspections each year (Source 2: FDA statement, May 6).
  • Even with advanced warning, the FDA finds deficiencies twice as often in overseas facilities (Source 2: FDA statement, May 6).
  • The proposed tariff on pharmaceuticals imported to the U.S. could cost drug companies as much as $1 trillion over a decade (Source: Bloomberg).

Sources:

  • https://www.usatoday.com/story/news/nation/2023/05/05/trump-executive-order-domestic-manufacturing-pharmaceuticals/55259317/
  • 2022 report by the U.S. Government Accountability Office (Source: "FDA's Foreign Inspection Program Needs Improvement")
  • FDA statement, May 6 (Source: "FDA to Review Policies to Improve Foreign Inspection Program")
  • https://www.phrma.org/
  • https://www.americancancersociety.org/
  • Hastings Center (Source: Rosemary Gibson's book, "China Rx: Exposing the Risks of America's Dependence on China for Medicine")